Investor Relations
We have developed this Investor Relations section to provide our investors (both existing and potential) and our other financial stakeholders with comprehensive, detailed and up to the minute information.
IR-related PDF documents
Syntopix One Page Summary July 2007
Syntopix Admission Document 2006
Syntopix Annual Report 2006 including Notice of Meeting and Proxy
Articles of Association 2005
Current share price
View further details on the LSE website here >>
Financial calendar
2007
- 19 April 2007 - Interim results 2007
- 18 October 2007 - Preliminary results 2007
- 12 December 2007 - Annual General Meeting
2006
- 28 September 2006 – Preliminary results 2006
- 12 December 2006 - Annual General Meeting
Significant shareholders (over 3%)
as at 13th February 2008
| Shareholder | No. of Shares |
% |
| Dr Rodney Harry Adams | 183,485 |
3.20% |
| Apollo Nominees Ltd | 193,000 |
3.37% |
| Chase Nominees Ltd |
225,989
|
3.94%
|
| Dr Jonanthan Howard Cove | 263,846 |
4.60% |
| Credit Suisse | 380,000 |
6.63% |
| Dr Elizabeth Anne Eady | 263,846 |
4.60% |
| Morstan Nominees Ltd | 225,989 |
3.94% |
| Ridings Early Growth Inv Co | 188,776 |
3.29% |
| Techtran Group Ltd |
1,020,885
|
17.81%
|
| University of Leeds | 390,000 |
6.80% |
| The Wellcome Trust | 519,168 |
9.06% |
| Pershing Keen Nominees Ltd |
470,371
|
8.21% |
4,325,325
|
||
| Others |
1,407,276
|
24.55% |
| Total issued share capital | 5,732,601 |
The percentage of shares not in public hands is 62.65%.
Investor relations contact
For all information about Syntopix please contact:
Dr. Stephen P. Jones - Chief Executive Officer
Email: spj@syntopix.com
Tel. +44 (0) 845 125 9204
Syntopix is located at:
Syntopix Group plc
The Institute of Pharmaceutical Innovation
University of Bradford
Bradford
BD7 1DP
Last updated: 13/02/2008